Single-agent interleukin-2 in the treatment of metastatic melanoma: A systematic review
- 31 August 2007
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 33 (5), 484-496
- https://doi.org/10.1016/j.ctrv.2007.04.003
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study GroupJournal of Clinical Oncology, 2006
- Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III StudyJournal of Clinical Oncology, 2004
- Results From a Randomized Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interleukin-2 Alone in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2002
- Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant MelanomaJournal of Clinical Oncology, 2000
- Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic MelanomaJournal of Clinical Oncology, 1999
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993Journal of Clinical Oncology, 1999
- Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2Annals of Surgery, 1998
- Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced CancerJNCI Journal of the National Cancer Institute, 1993
- Phase II Study of Intravenous Bolus Recombinant Interleukin-2 in Advanced Malignant Melanoma: Southwest Oncology Group StudyJNCI Journal of the National Cancer Institute, 1991
- Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer PatientsAnnals of Surgery, 1989